New-generation anti-obesity drugs: naltrexone/bupropion and liraglutide. An update for endocrinologists and nutritionists.

摘要: The prevalence of obesity increases worldwide and has a significant economic impact on health care systems. A comprehensive program lifestyle modification, including diet, exercise, behavior therapy is considered the first option for achieving weight loss. However, intrinsic difficulties associated with maintenance changes contribute to unsatisfactory long-term outcomes reported regain in management. In this context, pharmacological approaches are useful maximize non-pharmacological interventions management obesity. As add-on facilitate clinically past, anti-obesity drugs were limited. To date, landscape changed naltrexone/bupropion liraglutide have been recently added as new-generation treatment could represent important tools manage Liraglutide glucagon-like peptide 1 (GLP-1) receptor agonist that shares 97% homology native GLP-1 effects limbic system. 3.0 mg, combination hypocaloric diet increased physical activity, provides meaningful naltrexone 32 mg bupropion 360 acts mesolimbic reward pathway hypothalamic hunger system, two areas central nervous naltrexone/bupropion, an adjunct approved chronic adults or overweight ≥1 weight-related comorbidity. present review, we focused current evidence drugs, addressing main studies investigated these new treatment. Furthermore, semaglutide, currently pipeline potential future therapeutic use loss, reported.